[HTML][HTML] Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma
CA Ramos, NS Grover, AW Beaven… - Journal of clinical …, 2020 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2020•ncbi.nlm.nih.gov
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma - PMC Back
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage
Main Content Main Navigation Search PMC Full-Text Archive Search in PMC Advanced
Search User Guide Journal List J Clin Oncol PMC7655020 Other Formats PDF (1.6M) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles
Links to NCBI Databases Journal List J Clin Oncol PMC7655020 As a library, NLM provides …
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage
Main Content Main Navigation Search PMC Full-Text Archive Search in PMC Advanced
Search User Guide Journal List J Clin Oncol PMC7655020 Other Formats PDF (1.6M) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles
Links to NCBI Databases Journal List J Clin Oncol PMC7655020 As a library, NLM provides …
Abstract
PURPOSE
Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be effective. We show how the same approach of CAR T cells specific for CD30 (CD30. CAR-Ts) can be used to treat Hodgkin lymphoma (HL).
METHODS
ncbi.nlm.nih.gov
